【藥品訊息】 Symbicort RAPIhaler 吸必擴氣化噴霧劑 中文仿單 Symbicort RAPIhaler 吸必擴氣化噴霧劑 衛教單張

治療氣喘、COPD
Asthma (controller/maintenance): Treatment of asthma in patients ≥6 years of age
Chronic obstructive pulmonary disease: Maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema; to reduce COPD exacerbations

Long-Acting Beta2-Adrenergic Agonist / Inhalant Corticosteroid
1. Formoterol: Relaxes bronchial smooth muscle by selective action on beta2 receptors with little effect on heart rate; formoterol has a long-acting effect.
2. Budesonide: A corticosteroid which controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes/fibroblasts, and reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation.

Both agents are metabolized in the liver; urinary excretion is about 25% for formoterol (unchanged) and 60% for budesonide (as metabolites). Budesonide has an elimination half-life of 2 to 3 hours.

Prior hypersensitivity to budesonide or formoterol

C; Adverse events were observed in animal reproduction studies using this combination

According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk and the benefits.

Tremor, insomnia, restlessness, headache, hypokalemia, nausea, dry mouth, headache, insomnia, dyspepsia, abdominal pain, oral candidiasis, dysphonia, and respiratory infection

Asthma (controller/maintenance):
2 inhalations twice daily
Chronic obstructive pulmonary disease:
2 inhalations twice daily; Maximum 2 inhalations twice daily

For asthma maintenance (>5y/o): 2 inhalations twice daily

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution and monitor closely; may lead to accumulation of budesonide and formoterol.